v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 27, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 1,824 $ 1,142
Short-term investments 12,448 12,454
Trade accounts receivable, net of allowance for doubtful accounts: 2026—$426; 2025—$427 14,192 11,874
Inventories 10,022 10,654
Current tax assets 3,375 3,967
Other current assets 3,147 2,808
Total current assets 45,009 42,898
Long-term investments 1,453 1,621
Property, plant and equipment, net of accumulated depreciation: 2026—$18,344; 2025—$17,386 19,048 19,317
Identifiable intangible assets, net 45,956 53,731
Goodwill 71,464 71,264
Noncurrent deferred tax assets and other noncurrent tax assets 11,591 9,699
Other noncurrent assets 10,024 9,631
Total assets 204,544 208,160
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2026—$2,604; 2025—$2,997 2,674 3,154
Trade accounts payable 4,070 5,240
Dividends payable 0 2,445
Income taxes payable 438 3,103
Accrued compensation and related items 3,398 3,610
Other current liabilities 21,146 19,432
Total current liabilities 31,726 36,984
Long-term debt 59,997 61,641
Pension and postretirement benefit obligations 1,921 2,041
Noncurrent deferred tax liabilities 1,936 2,401
Other taxes payable 4,247 3,591
Other noncurrent liabilities 15,416 14,725
Total liabilities 115,243 121,385
Commitments and Contingencies
Common stock 482 481
Additional paid-in capital 95,355 94,469
Treasury stock (115,195) (115,015)
Retained earnings 115,328 114,610
Accumulated other comprehensive loss (6,969) (8,069)
Total Pfizer Inc. shareholders’ equity 89,001 86,476
Equity attributable to noncontrolling interests 299 299
Total equity 89,301 86,775
Total liabilities and equity $ 204,544 $ 208,160